JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics (NASDAQ:MAZE) had its price target upped by JPMorgan Chase & Co. from $27.00 to $37.00 in a report published on Monday,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other analysts also recently weighed in on the company. Wedbush started coverage on Maze Therapeutics in a research note on Tuesday, July 8th. They set an “outperform” rating and a $17.00 target price for the company. BTIG Research upped their price target on Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Guggenheim raised their price objective on shares of Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Maze Therapeutics in a research note on Thursday, September 18th. Finally, Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $33.83.

Maze Therapeutics Price Performance

Shares of MAZE stock opened at $25.20 on Monday. The stock’s 50 day simple moving average is $17.23 and its 200 day simple moving average is $13.27. Maze Therapeutics has a twelve month low of $6.71 and a twelve month high of $28.37.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.02.

Insider Activity

In other news, Director Richard H. Scheller sold 20,744 shares of the stock in a transaction on Monday, September 15th. The shares were sold at an average price of $22.37, for a total value of $464,043.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Institutional Investors Weigh In On Maze Therapeutics

Large investors have recently modified their holdings of the stock. Alphabet Inc. bought a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $26,561,000. Invesco Ltd. acquired a new position in Maze Therapeutics during the first quarter worth $226,000. Nuveen LLC bought a new position in shares of Maze Therapeutics during the first quarter valued at $125,000. Bank of New York Mellon Corp acquired a new stake in shares of Maze Therapeutics in the 1st quarter valued at $190,000. Finally, Octagon Capital Advisors LP bought a new stake in shares of Maze Therapeutics in the 1st quarter worth about $5,153,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.